| Jun 20 |
Why Wall Street Is Chasing Ozempic Wannabes
|
| Jun 19 |
Gilead and Kite Pharma Celebrates Pride Month
|
| Jun 19 |
Shareholders in Gilead Sciences (NASDAQ:GILD) are in the red if they invested a year ago
|
| Jun 17 |
Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender
|
| Jun 14 |
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
|
| Jun 14 |
EU to require additional cancer risk labeling on CAR T therapies
|
| Jun 14 |
Gilead Stock Gains. It’s Trying to Get Into the Obesity Drug Game.
|
| Jun 14 |
Gilead spikes as Jefferies highlights weight loss prospects
|
| Jun 14 |
Gilead Sciences Inc's Dividend Analysis
|
| Jun 14 |
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
|
